Challenges confronting precision medicine in the context of inherited retinal disorders

Pei-Wen Chiang, Michael B. Gorin

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

“Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes — and to give all of us access to the personalized information we need to keep ourselves and our families healthier.” - President Barack Obama, State of the Union Address, January 20, 2015. This new initiation of precision medicine has generated excitement and promises of improved health outcomes. The challenge is to use individual-specific information to provide optimal, cost-effective customized care. This entails a comprehensive knowledge of individual behaviors, diet and exposures as well as a complete past medical history of an individual and detailed (preferably quantitative) descriptions of clinical findings and measurements. The molecular genetics of an individual as well as that of diseased tissues such as cancers are an integral part of this program. Molecular diagnostics are especially important for individuals who are experiencing disorders that are clearly traceable to genetic variations. However, to realize the potential of combining genetics with non-genetic factors that contribute to disease, we will need to have a much better understanding of how genetic variants contribute to normal and pathologic physiology, and how to classify these genetic variants, which are often uncharacterized. In this paper we will consider the promise and challenges of molecular diagnostic testing for rare genetic disorders, with a focus on inherited retinal disorders (IRD), and leave the consideration of identifying, quantifying, and assessing non-genetic risk factors for disease to others.

Original languageEnglish (US)
Pages (from-to)195-205
Number of pages11
JournalExpert Review of Precision Medicine and Drug Development
Volume1
Issue number2
DOIs
StatePublished - Mar 3 2016

Fingerprint

Precision Medicine
Molecular Diagnostic Techniques
Access to Information
Inborn Genetic Diseases
Molecular Pathology
Molecular Biology
Neoplasms
Diet
Costs and Cost Analysis
Health

Keywords

  • genes
  • genetic testing
  • Inherited retinal dystrophy
  • molecular diagnosis
  • next generation sequencing
  • NGS
  • precision medicine
  • retina
  • retinitis pigmentosa

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Molecular Medicine
  • Genetics

Cite this

Challenges confronting precision medicine in the context of inherited retinal disorders. / Chiang, Pei-Wen; Gorin, Michael B.

In: Expert Review of Precision Medicine and Drug Development, Vol. 1, No. 2, 03.03.2016, p. 195-205.

Research output: Contribution to journalReview article

@article{be1615152c9b43cd90e0589a2f4b0843,
title = "Challenges confronting precision medicine in the context of inherited retinal disorders",
abstract = "“Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes — and to give all of us access to the personalized information we need to keep ourselves and our families healthier.” - President Barack Obama, State of the Union Address, January 20, 2015. This new initiation of precision medicine has generated excitement and promises of improved health outcomes. The challenge is to use individual-specific information to provide optimal, cost-effective customized care. This entails a comprehensive knowledge of individual behaviors, diet and exposures as well as a complete past medical history of an individual and detailed (preferably quantitative) descriptions of clinical findings and measurements. The molecular genetics of an individual as well as that of diseased tissues such as cancers are an integral part of this program. Molecular diagnostics are especially important for individuals who are experiencing disorders that are clearly traceable to genetic variations. However, to realize the potential of combining genetics with non-genetic factors that contribute to disease, we will need to have a much better understanding of how genetic variants contribute to normal and pathologic physiology, and how to classify these genetic variants, which are often uncharacterized. In this paper we will consider the promise and challenges of molecular diagnostic testing for rare genetic disorders, with a focus on inherited retinal disorders (IRD), and leave the consideration of identifying, quantifying, and assessing non-genetic risk factors for disease to others.",
keywords = "genes, genetic testing, Inherited retinal dystrophy, molecular diagnosis, next generation sequencing, NGS, precision medicine, retina, retinitis pigmentosa",
author = "Pei-Wen Chiang and Gorin, {Michael B.}",
year = "2016",
month = "3",
day = "3",
doi = "10.1080/23808993.2016.1152159",
language = "English (US)",
volume = "1",
pages = "195--205",
journal = "Expert Review of Precision Medicine and Drug Development",
issn = "2380-8993",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Challenges confronting precision medicine in the context of inherited retinal disorders

AU - Chiang, Pei-Wen

AU - Gorin, Michael B.

PY - 2016/3/3

Y1 - 2016/3/3

N2 - “Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes — and to give all of us access to the personalized information we need to keep ourselves and our families healthier.” - President Barack Obama, State of the Union Address, January 20, 2015. This new initiation of precision medicine has generated excitement and promises of improved health outcomes. The challenge is to use individual-specific information to provide optimal, cost-effective customized care. This entails a comprehensive knowledge of individual behaviors, diet and exposures as well as a complete past medical history of an individual and detailed (preferably quantitative) descriptions of clinical findings and measurements. The molecular genetics of an individual as well as that of diseased tissues such as cancers are an integral part of this program. Molecular diagnostics are especially important for individuals who are experiencing disorders that are clearly traceable to genetic variations. However, to realize the potential of combining genetics with non-genetic factors that contribute to disease, we will need to have a much better understanding of how genetic variants contribute to normal and pathologic physiology, and how to classify these genetic variants, which are often uncharacterized. In this paper we will consider the promise and challenges of molecular diagnostic testing for rare genetic disorders, with a focus on inherited retinal disorders (IRD), and leave the consideration of identifying, quantifying, and assessing non-genetic risk factors for disease to others.

AB - “Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes — and to give all of us access to the personalized information we need to keep ourselves and our families healthier.” - President Barack Obama, State of the Union Address, January 20, 2015. This new initiation of precision medicine has generated excitement and promises of improved health outcomes. The challenge is to use individual-specific information to provide optimal, cost-effective customized care. This entails a comprehensive knowledge of individual behaviors, diet and exposures as well as a complete past medical history of an individual and detailed (preferably quantitative) descriptions of clinical findings and measurements. The molecular genetics of an individual as well as that of diseased tissues such as cancers are an integral part of this program. Molecular diagnostics are especially important for individuals who are experiencing disorders that are clearly traceable to genetic variations. However, to realize the potential of combining genetics with non-genetic factors that contribute to disease, we will need to have a much better understanding of how genetic variants contribute to normal and pathologic physiology, and how to classify these genetic variants, which are often uncharacterized. In this paper we will consider the promise and challenges of molecular diagnostic testing for rare genetic disorders, with a focus on inherited retinal disorders (IRD), and leave the consideration of identifying, quantifying, and assessing non-genetic risk factors for disease to others.

KW - genes

KW - genetic testing

KW - Inherited retinal dystrophy

KW - molecular diagnosis

KW - next generation sequencing

KW - NGS

KW - precision medicine

KW - retina

KW - retinitis pigmentosa

UR - http://www.scopus.com/inward/record.url?scp=85041422660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041422660&partnerID=8YFLogxK

U2 - 10.1080/23808993.2016.1152159

DO - 10.1080/23808993.2016.1152159

M3 - Review article

AN - SCOPUS:85041422660

VL - 1

SP - 195

EP - 205

JO - Expert Review of Precision Medicine and Drug Development

JF - Expert Review of Precision Medicine and Drug Development

SN - 2380-8993

IS - 2

ER -